Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total value of $2,435,400.00. Following the sale, the chief executive officer owned 666,195 shares in the company, valued at $54,081,710.10. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, February 25th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.26, for a total transaction of $2,707,800.00.

Kymera Therapeutics Price Performance

NASDAQ KYMR traded down $2.34 on Wednesday, hitting $81.51. The company had a trading volume of 754,528 shares, compared to its average volume of 705,717. The company has a market capitalization of $6.65 billion, a PE ratio of -22.15 and a beta of 2.28. The company’s fifty day moving average price is $84.70 and its 200-day moving average price is $76.16. Kymera Therapeutics, Inc. has a 12-month low of $28.06 and a 12-month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.Kymera Therapeutics’s revenue was down 60.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.88) EPS. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.65 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on KYMR shares. Morgan Stanley reissued an “overweight” rating and issued a $123.00 price target on shares of Kymera Therapeutics in a report on Thursday, February 26th. BTIG Research cut their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Royal Bank Of Canada reissued an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a report on Thursday, February 26th. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 price target for the company. Finally, Stephens boosted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $118.90.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP raised its position in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC raised its position in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after buying an additional 1,061,957 shares during the last quarter. Finally, State Street Corp raised its position in shares of Kymera Therapeutics by 9.4% in the fourth quarter. State Street Corp now owns 2,209,837 shares of the company’s stock valued at $171,947,000 after buying an additional 190,383 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.